Assessment and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Comparison of Imaging Modalities and Future Perspectives.
Valeria RomeoGiuseppe AccardoTeresa PerilloLuca BassoNunzia GarbinoEmanuele NicolaiSimone MaureaMarco SalvatorePublished in: Cancers (2021)
Neoadjuvant chemotherapy (NAC) is becoming the standard of care for locally advanced breast cancer, aiming to reduce tumor size before surgery. Unfortunately, less than 30% of patients generally achieve a pathological complete response and approximately 5% of patients show disease progression while receiving NAC. Accurate assessment of the response to NAC is crucial for subsequent surgical planning. Furthermore, early prediction of tumor response could avoid patients being overtreated with useless chemotherapy sections, which are not free from side effects and psychological implications. In this review, we first analyze and compare the accuracy of conventional and advanced imaging techniques as well as discuss the application of artificial intelligence tools in the assessment of tumor response after NAC. Thereafter, the role of advanced imaging techniques, such as MRI, nuclear medicine, and new hybrid PET/MRI imaging in the prediction of the response to NAC is described in the second part of the review. Finally, future perspectives in NAC response prediction, represented by AI applications, are discussed.
Keyphrases
- neoadjuvant chemotherapy
- end stage renal disease
- artificial intelligence
- transcription factor
- high resolution
- chronic kidney disease
- ejection fraction
- newly diagnosed
- locally advanced
- magnetic resonance imaging
- squamous cell carcinoma
- palliative care
- machine learning
- patient reported outcomes
- healthcare
- young adults
- coronary artery disease
- peritoneal dialysis
- big data
- radiation therapy
- magnetic resonance
- mass spectrometry
- pain management
- percutaneous coronary intervention
- computed tomography
- acute coronary syndrome
- surgical site infection